See more : Gloster Limited (GLOSTERLTD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Alaunos Therapeutics, Inc. (TCRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alaunos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SANVO Fine Chemicals Group Limited (0301.HK) Income Statement Analysis – Financial Results
- Danal Co., Ltd. (064260.KQ) Income Statement Analysis – Financial Results
- RHI Magnesita N.V. (RHIM.VI) Income Statement Analysis – Financial Results
- Hybrid Software Group PLC (GLOG.BR) Income Statement Analysis – Financial Results
- Nation Group (Thailand) Public Company Limited (NATION.BK) Income Statement Analysis – Financial Results
Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 4.80M | 2.76M | 740.00K | 1.13M | 629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | -95,960.00% | 5.58% | -85.93% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 16.28M | 25.02M | 49.64M | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 773.14K | 8.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 971.00K | 529.00K | -1.20M | 385.00K | 813.00K | 631.00K | 465.00K | 134.00K | 12.00K | -5.00K | -579.00K | -13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 0.00 | 0.00 | 486.00 | 42.51K | 74.14K |
| Operating Expenses | 29.47M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Cost & Expenses | 34.27M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.92M | 3.15M | 1.18M | 0.00 | 0.00 | 0.00 | 830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.32M | 2.76M | 2.60M | 1.13M | 629.00K | 573.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | -53.33M | -53.12M | -165.01M | -119.73M | -43.50M | -56.98M | -102.17M | -71.40M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -5.65M | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | -618,080.00% | -1,187.85% | -19,112.81% | 0.00% | 0.00% | -37,030.14% | -817.00% | -2,407.56% | -2,772.39% | -4,022.00% | -7,270.00% | -13,445.13% | -11,807.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -34.27M | -35.11M | -77.55M | -80.36M | 2.26M | -53.91M | -53.49M | -165.31M | -120.10M | -43.50M | -57.71M | -102.17M | -71.40M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | -685,340.00% | -1,201.40% | -19,484.67% | 0.00% | 0.00% | -36,921.92% | -837.27% | -2,409.37% | -2,772.39% | -3,168.17% | -7,214.13% | -12,771.13% | -10,704.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | -873.00K | -2.63M | -1.20M | 385.00K | -59.94M | 789.00K | -830.00K | 10.00K | 12.00K | 11.72M | 606.00K | 6.04M | 7.62M | -8.12M | 4.47M | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -35.14M | -37.73M | -78.75M | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0.00 | -17.86M | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | -702,800.00% | -1,291.24% | -19,786.68% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | -133.00K | -1.86M | -1.13M | 60.12M | -947.00K | 2.13M | 114.00K | -12.00K | -23.44M | -1.79M | -12.09M | -15.24M | 16.25M | -8.95M | -388.00K | -1.96M | -1.25M | -270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | -702,800.00% | -1,286.69% | -19,320.10% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Diluted | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Weighted Avg Shares Out | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q2 2022 Results - Earnings Call Transcript
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Danielle Dudgeon - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research and Development Abhishek...
Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open...
Best Penny Stocks For July 2022? 5 To Watch Right Now
Penny stocks to watch right now. The post Best Penny Stocks For July 2022?
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022
Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?
Check These 3 Penny Stocks Out in Mid-June 2022
Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out in Mid-June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research &...
Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting...
Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alex Lobo - Stern, Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President, Research and Development Mike Wong...
Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research &...
Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open...
Source: https://incomestatements.info
Category: Stock Reports